Pioneer

Prostate cancer is the second commonest cancer in men, 1 in 8 men will be diagnosed with prostate cancer during their lifetime, accounting for 9% of all cancer deaths among men in Europe. The socio-economic burden associated with PCa is predicted to dramatically increase in the coming years due to our ageing population. Studies have reported a prevalence of 59% by the age of 79 years.

PIONEER’s unique approach is to firstly identify critical evidence gaps in prostate cancer care through a detailed prioritisation exercise including all stakeholders (i.e. clinicians, patients, researchers, industry etc.). PIONEER will then standardise and integrate existing ‘big data’ from high quality and multidisciplinary data sources from prostate cancer patients across different stages of the disease into a single innovative data platform. Based on a unique set of methodologies and advanced analytical methods, PIONEER will attempt to transform the field of prostate cancer care with particular focus on improving prostate cancer-related outcomes, health system efficiency and the quality of health and social care delivered to all prostate cancer patients and their families. In addition, PIONEER will aim to provide standardised care pathways for all clinical centres across Europe.

https://prostate-pioneer.eu/

Partners

Astellas Pharma
Bayer
Cancer Intelligence Limited
Covance
European Alliance for Personalised Medicine
European Association of Urology
European Cancer Patient Coalition
European Institute for Systems Biology and Medicine
European Organisation for Research and Treatment of Cancer
Erasmus Universitair Medisch Centrum Rotterdam
Fraunhofer IZI
Goeteborgs Universitet
Imperial College of Science Technology and Medicine
International Consortium for Health Outcomes Measurement
Janssen Pharmaceutical
King’s College London
Lund University
Orion Corporation
Pinsent Masons LLP
Radboud University Medical Center
Sanofi
SAS Institute
Swedish Institute for Health Economics
Technische Universität Dresden
The Hyve B.V
The University Court of the University of Aberdeen
Ttopstart
Universitaetsklinikum Hamburg-Eppendorf
University of Tampere
Universita Vita-Salute San Raffaele
Varian Medical Systems
Weizmann Institute of Science

BD4BO
Big Data for Better Outcomes				Contact for BD4BO Website
This website has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2) under grant agreement No. 116055. This Joint Undertaking receives support from the European Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).				Semmelweis University – Health Services Management Training Centre, Budapest Email: doit.communication@emk.sote.hu Legal notice

Definitions
Big Data	BD4BO
“Big data in health refers to largely routinely or automatically collected datasets, which are electronically captured and stored. It is reusable in the sense of multipurpose data and comprises the fusion and connection of existing databases for the purpose of improving health and health system performance.” (European Commission, Study on Big Data in Public Health, Telemedicine and Healthcare. 2016.)	Big Data for Better Outcomes is a comprehensive European research programme funded by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2) aiming to develop key enablers to support healthcare system transformation through the use of big data.
DO->IT	Core outcome sets
“Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation” is the Coordination and Support Action project of the BD4BO programme.	the agreed minimum standardised set of outcomes that should be measured and reported in trials or other research on a specific condition.